Intra-aortic adrenaline titration during cardiac arrest Authors: James E. Manning, Ed B. G. Barnard, Jon Barratt, Paul S. C. Rees Published: 2026 ABSTRACT Adrenaline has been the principal vasoactive drug in cardiac arrest for decades. It reliably increases return of spontaneous circulation but has not shown a consistent improvement in long-term survival with favourable neurological outcome. High cumulative doses are associated with poorer neurological outcomes among survivors. Unreliable systemic delivery of intravenous adrenaline during the low-flow state of cardiopulmonary resuscitation (CPR) may be responsible for this disconnect. When return of spontaneous circulation follows multiple doses, abrupt mobilisation of accumulated adrenaline may be deleterious and contribute to post-resuscitation shock. We describe the “Adrenaline Dilemma”: patients with the lowest coronary perfusion pressure are most in need of vasoconstriction to improve blood flow, yet they are also those in whom intravenous adrenaline is least likely to circulate promptly; conversely, patients with adequate coronary perfusion pressure may be exposed to excessive dosing. Thoracic aortic catheterisation via femoral arterial access provides rapid systemic arterial drug delivery and real-time haemodynamic feedback. Continuous aortic pressure monitoring allows optimisation of CPR mechanics and rapid titration of intra-aortic adrenaline as small, diluted boluses or continuous infusion targeting an observed physiological endpoint. Preclinical experiments and early prehospital clinical experience have shown favourable results. Haemodynamically guided intra-aortic adrenaline administration during CPR is a plausible, testable endovascular adjunct and warrants prospective evaluation within modern resuscitation pathways. Adrenaline has been the principal vasoactive drug used in cardiac arrest since the 1960s. It reliably increases return of spontaneous circulation (ROSC) but has not shown a consistent benefit in long-term survival with favourable neurological outcome [1, 2]. Observational and trial data demonstrate that higher cumulative doses, 3–5 mg or more, are associated with poorer neurological outcomes among survivors [2, 3]. Some investigators now question the routine use of adrenaline or propose dose limits [3]. Paradoxically, adrenaline promotes ROSC, the first critical step to survival, but it can adversely affect long-term neurological outcome, making its ultimate value questionable. The challenge may not be the intrinsic haemodynamic efficacy of adrenaline, but unreliable systemic delivery in the low-flow state of cardiopulmonary resuscitation (CPR) [4]. We propose that rapid systemic arterial delivery by direct intra-aortic administration, guided by real-time haemodynamic feedback, may more consistently achieve therapeutic goals. Intravenous drug delivery in cardiac arrest Parenteral administration requires sufficient circulation to deliver drugs to systemic effector sites. Blood flow during CPR is highly variable and unpredictable. Although using an intravenous site close to the heart may shorten circulation time, drugs must still pass through the pulmonary circulation before reaching the systemic arterial tree, where impaired pulmonary blood flow and gas exchange during CPR may further hinder effective delivery [5]. If ROSC is achieved after multiple adrenaline doses, a large amount of adrenaline may be mobilized from the venous “reservoir” leading to excessive adrenergic stimulation with refractory loss of sympathetic responsiveness [2, 6]. The “Adrenaline Dilemma” The primary benefit of adrenaline during CPR is arterial vasoconstriction resulting in increased aortic pressure (AoP) and increased coronary perfusion pressure (CPP), thereby enhancing myocardial perfusion and likelihood of ROSC. In all circumstances, CPR is a “low-flow” state, but patients with low CPP likely have especially poor drug circulation time. Unfortunately, such patients are most in need of adrenaline-mediated vasoconstriction to increase AoP and coronary perfusion. Conversely, if CPP is good (e.g., > 30 mmHg), one or two standard adrenaline doses (1 mg) may be excessive and have detrimental effects. The authors’ present the concept of an “Adrenaline Dilemma,” whereby exogenously delivered adrenaline is poorly circulated in patients who need it the most, and likely circulated best in patients who may not need it. Determining where along this spectrum a patient lies requires an arterial catheter. Intra-aortic adrenaline in cardiac arrest Adrenaline needs to be rapidly circulated to the peripheral systemic arteries. To minimize delay and potential adverse effects from crossing the pulmonary circulation, intra-aortic administration would facilitate immediate peripheral arterial delivery to exert its vasoconstrictor effect. Aortic catheterization provides for: (1) assessment of CPR-systolic/diastolic AoP, (2) adjustment in CPR (compression site, rate, depth, etc.) to optimize blood flow, and (3) rapid titration of intra-aortic adrenaline, either small boluses with an increased frequency (100–250 mcg, q 1 min) or continuous infusion (0.1–1 mcg/kg/min) titrated to optimal therapeutic effect, observed in real time as CPR-diastolic AoP (surrogate for CPP). The challenges are technical skill required and time to catheter insertion. Insertion of an aortic catheter is more complex than a peripheral venous catheter, but most resuscitation clinicians have sufficient vascular access skills to learn safe ultrasound-guided femoral arterial access and placement of a small (i.e., 5–6 Fr) thoracic aortic catheter [7]. Early aortic catheterization will provide the greatest potential benefit and seems reasonable if resuscitation will continue for more than five minutes. Intra-aortic adrenaline addresses the “Adrenaline Dilemma” by making rapid peripheral arterial delivery consistent in all cardiac arrest patients. Preclinical study In a laboratory ventricular fibrillation study, intra-aortic adrenaline via a thoracic aortic catheter produced a more rapid increase in AoP and a consistent pattern of response compared to central venous adrenaline via a right atrial catheter [8]. Adrenaline was diluted in both groups to facilitate rapid distribution. Maximal AoP response with intra-aortic adrenaline was reached in 30–50 s. Maximal CPR-diastolic AoP was tightly correlated with the AoP before adrenaline. Rapid titration of intra-aortic adrenaline achieved optimal AoP within a few minutes without excessive adrenaline doses, and the initial adrenaline dose may be guided by the initial CPR-diastolic AoP observed. Clinical experience A physician response system was developed to perform prehospital thoracic aortic and central venous catheterizations in out-of-hospital cardiac arrests [9]. CPR-diastolic AoP and central venous pressure were used to calculate CPP. CPR mechanics were adjusted to optimize CPP and small doses (100–250 mcg) of adrenaline (diluted in saline) were given intra-aortic at 1-min intervals until ROSC was achieved or maximal AoP response was observed. In 22 patients, 13 (60%) had ROSC and 11 (50%) survived to hospital admission. The total dose of adrenaline to achieve ROSC in the 13 patients did not exceed 1 mg. ROSC was highest in patients undergoing aortic catheterization within about 15–20 min of arrest. This clinical experience suggests that effective delivery of adrenaline via the intra-aortic route can yield ROSC at much smaller total doses than typically seen with intravenous adrenaline. Endovascular resuscitation and intra-aortic adrenaline Aortic catheterization during resuscitation prior to 2010 was regarded to be too complicated. However, the development of aortic balloon catheters for non-compressible hemorrhage in trauma led to reappraisal of central arterial access during resuscitation [10]. Increasingly, portable extracorporeal membrane oxygenation devices are being used to initiate prehospital extracorporeal CPR (ECPR) [11, 12]. Concurrently, newer ultrasound technologies have made prehospital ultrasound guidance for femoral vascular access an available tool [13–15]. All these technologies have spurred momentum toward prehospital endovascular resuscitation or rapid transport for in-hospital endovascular resuscitation [15]. Thoracic aortic catheterization with intra-aortic adrenaline is procedurally similar to aortic balloon catheter placement and less complex than ECPR, offering a potential intermediate step toward broader endovascular resuscitative strategies. Conclusion Adrenaline improves ROSC, the essential first step toward survival, yet routine intravenous administration does not reliably translate to improved long-term neurological outcomes. We propose that a major limitation of current practice is the unpredictable systemic circulation of intravenous adrenaline during CPR. Thoracic aortic catheterization with haemodynamically-guided intra-aortic adrenaline delivery offers a plausible method to achieve consistent arterial delivery, permit tailored dosing, and align therapy with individual physiological response. Research investigating intra-aortic adrenaline within endovascular resuscitation frameworks is warranted.